A detailed history of Jpmorgan Chase & CO transactions in Journey Medical Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 469 shares of DERM stock, worth $2,602. This represents 0.0% of its overall portfolio holdings.

Number of Shares
469
Previous 20 2245.0%
Holding current value
$2,602
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$4.22 - $5.91 $1,894 - $2,653
449 Added 2245.0%
469 $2,000
Q2 2024

Aug 12, 2024

BUY
$3.31 - $5.94 $16 - $29
5 Added 33.33%
20 $0
Q1 2024

May 10, 2024

SELL
$2.92 - $5.47 $283 - $530
-97 Reduced 86.61%
15 $0
Q4 2023

Feb 12, 2024

BUY
$2.7 - $7.96 $283 - $835
105 Added 1500.0%
112 $0
Q3 2023

Nov 14, 2023

BUY
$1.66 - $2.97 $11 - $20
7 New
7 $0

Others Institutions Holding DERM

About Journey Medical Corp


  • Ticker DERM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 11,596,500
  • Market Cap $64.4M
  • Description
  • Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat...
More about DERM
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.